semaglutide clearance + B6 | Boston Ozempic vs Mounjaro: Comparing GLP‑1

The SUSTAIN 6 cardiovascular outcomes trial, which followed patients for a median of 2.1 years, demonstrated a 26% reduction in the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke compared to placebo

Patients can choose to inject subcutaneously in the abdomen, upper thigh, or upper arm, rotating between these injection sites systematically to minimize skin irritation and guarantee peak absorption

Shaking can damage the delicate proteins in semaglutide, reducing its effectiveness

The efficacy of OZEMPIC was compared with placebo, sitagliptin, exenatide extended-release (ER), and insulin glargine